Although our previous studies converge on the prognostic value of ficoll-enriched CTCs for BC patients [12,13,25,30,41], the availability of high CTC counts for downstream analysis would help to better define the incidence and role of Fas/FasL expression on CTCs. The gene discussed is FASLG; the disease is breast cancer.